Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong One Year Shareholder Return

Arrowhead Pharmaceuticals (ARWR) has drawn fresh attention after its recent share move, with the stock up about 8% on the day and roughly 7% over the past week.

See our latest analysis for Arrowhead Pharmaceuticals.

That sharp daily move comes after a softer few months, with the 30 day share price return at about a 3.8% decline and the 90 day share price return at about a 13.3% decline. Yet the 1 year total shareholder return is very large at about 336%, so short term momentum looks more like a pause in a much stronger long term run.

If Arrowhead’s jump has you thinking about where else growth stories might emerge in biotech, it could be a good moment to scan for other healthcare names using the 36 healthcare AI stocks

With Arrowhead’s shares moving sharply and the stock trading below analyst targets and some intrinsic value estimates, investors may wonder whether there is still potential upside or whether the market is already pricing in future growth.

Most Popular Narrative: 5.2% Undervalued

Arrowhead’s most followed narrative pegs fair value at about $64.08 per share, only slightly above the recent $60.77 close, which keeps expectations finely balanced.

Progress in RNAi delivery technology (TRiM™ platform), pipeline breadth in both prevalent and rare/orphan indications, and first-mover potential in CNS and adipose tissue RNAi expand Arrowhead's competitive edge as advancements in genomics and precision medicine increase the feasibility and personalization of RNAi therapies. This supports stronger projected net margins and long-term earnings growth if adoption broadens.

Read the complete narrative.

Curious what assumptions sit behind that modest discount to fair value? The narrative leans heavily on future margins, pipeline optionality, and a rich earnings multiple that assumes a very specific growth path.

Result: Fair Value of $64.08 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that story could shift quickly if key partners pull back on milestone payments or if late stage trial or regulatory setbacks affect the RNAi pipeline.

Find out about the key risks to this Arrowhead Pharmaceuticals narrative.

Another Angle on Valuation

The narrative around Arrowhead leans on a fair value of about $64.08 per share, only slightly above the recent $60.77 price. Yet on earnings, the stock trades on a P/E of 42.1x versus 16.9x for the US Biotechs industry, a 19.7x peer average and a 19.8x fair ratio. This points to a much richer setup and raises the question of whether this reflects quality being rewarded or expectations stretching too far.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment finely balanced, this is a good moment to look through the data yourself and decide how comfortable you are with the current setup. To see what optimistic investors are focusing on, review the 2 key rewards.

Looking for more investment ideas?

If you are weighing what to do after a move like Arrowhead’s, do not stop at a single stock. Broaden your watchlist with targeted idea lists instead.

• Spot potential turnaround candidates early by scanning 29 elite penny stocks with strong financials that pass strict financial filters, before they sit on everyone else’s radar.
• Zero in on quality at a reasonable price by reviewing the 55 high quality undervalued stocks that combine solid fundamentals with appealing valuations.
• Strengthen the core of your portfolio by using the solid balance sheet and fundamentals stocks screener (39 results) to focus on companies with robust finances and staying power.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com